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Background. There are only a few comprehensive studies of adherence to ART and its challenges in Africa. This paper aims to
assess the evidence on the challenges and prospects of ART adherence in sub-Saharan Africa. Methods. The authors reviewed
original and review articles involving HIV-positive individuals that measured adherence to ART and its predictors in the past
decade. Findings. Against expectations, sub-Saharan Africa patients have similar or higher adherence levels compared to those of
developedcountries.Thechallenges toARTadherence includefactorsrelatedtopatientsandtheirfamilies,socioeconomicfactors,
medication, and healthcare systems. Conclusion. Despite good adherence and program-related ﬁndings, antiretroviral treatment
is challenged by a range of hierarchical and interrelated factors. There is substantial room for improvement of ART programs in
sub-Sahara African countries.
1.Introduction
Acquired immune deﬁciency syndrome (AIDS) is one of the
most destructive epidemics the world has ever witnessed.
Presently an estimated 33.4 million people are living with
HIV worldwide, nearly two-thirds of these live in sub-
Saharan Africa [1].
Antiretroviraltherapy(ART)hasshowntodelayprogres-
sion to AIDS, resulting in a greater and more sustained viro-
logic and immunologic response [2] and improve survival
[3].Insub-SaharanAfrica,therehasbeenadramaticincrease
in the number of HIV/AIDS patients on antiretroviral
treatment from just 100,000 persons in 2003 to 3.9 million
in 2009 involving close to 40% of those in need of the
treatment [4]. Two sub-Saharan Africa countries, Botswana
andRwanda,haveachieveduniversalaccesstarget(treatment
coverage of 80% or more of patients in need) at the end of
2009[4],whilecountriessuchasEthiopia,Zambia,Namibia,
and Senegal are moving closer to the same target having
covered 50–80% of patients in need of treatment [4].
According to recent studies, ART regimens require 70–
90% adherence in order to be eﬀective [5]. However, sus-
taining adherence to antiretroviral therapy (ART) over the
long term requires accurate and consistent monitoring, and
this is a particular challenge for countries in sub-Saharan
Africa [5]. It is further challenged by various social and
clinical obstacles [5] where inadequate suppression of viral
replication by ART are resulting due to poor adherence to
therapy, low potency of the antiretroviral regimens, viral
resistance to antiretroviral medications, and pharmacoki-
neticinteractions[6]causinginadequatedrugdelivery[5,7].
The transmissibility of the antiretroviral resistant viruses
from person to person further compounds the problem as
a clinical and public health challenge [8, 9].
Adherence is deﬁned as taking medications or interven-
tions correctly according to prescription. There are diﬀerent
methods forassessingadherenceandthelevelofadherenceis
speciﬁc not only to places and patient groups but also to the
method of adherence measurement used [10]. They include
direct methods such as biologic markers and body ﬂuid
assays, or indirect methods such as self-report, interview,
pill counts, pharmacy records, computerized medication
caps, and viral load monitoring. While a combination of
these methods may be employed, patient self-report is the
most widely used [11] given its ease of implementation
and use of already existing resources. Studies have also2 AIDS Research and Treatment
indicated that self-reports correlate well with both viral
load and clinical outcomes [12, 13]. Use of computerized
medication caps and monitoring of surrogate markers seems
reliable and less prone to respondent bias. However, the
advanced technology, high cost, and logistic requirements
have precluded their wider application in sub-Saharan Africa
[14]. In developing countries, pharmacy reﬁll reports and
self-reports are commonly implemented for adults [5, 15],
while caregiver reports are employed for children [11, 16,
17]. Currently, there are no gold standard methods for
measuring adherence [5].
There are only very few studies that investigate adherence
to ART in sub-Saharan Africa. The aim of this paper is to
assess the challenges of adherence to ART and to identify the
factors that contribute to poor adherence.
1.1. Current Estimates of Adherence. Studies indicate that
despite earlier fears of poor medication adherence [6,
18], patients in developing countries are able to achieve
adherence levels similar to or higher than those of patients in
developed countries [19]. For instance, a review by Vreeman
and colleagues indicated that the majority of the studies in
developing countries report adherence levels of more than
75% (range 45–100%) [11], while in developed countries
the majority report less than 75% (range 20–100%) [17].
Another systematic review by Mills and colleagues obtained
a pooled estimate of adequate adherence by sub-Saharan
Africa patients of 77% (95% conﬁdence interval, 68–85%;
based on a total of 12,116 patients), whereas the ﬁgure for
North American patients was 55% (95% conﬁdence interval
49–62%; based on a total of 17,573 patients) [20]. The
same study concluded that adherence is a concern in North
America.
1.2. Patient- and Family-Related Challenges. With regard to
children, if the mother (or other caregiver) is infected, then
she is struggling with her own illness, psychosocial factors,
medication regimens, and most often ﬁnancial burden due
to expenses incurred on her own therapy, child’s therapy,
and associated cost of medical treatment [21, 22]. All of
these produce negative inﬂuences on adherence. Empirical
evidence increasingly suggest that user fees in some centers
forantiretroviraltherapy(ART)andHIV/AIDScaredecrease
adherence [23, 24]. These factors on top of the caregivers’
and patients’ experience, knowledge and beliefs on ART
[25], reduce the caregiver’s ability to provide proper care
to the child, thereby aﬀecting the necessary adherence over
time [26–31]. Furthermore, factors such as age (especially
infancy and adolescence have a negative eﬀect) [19], refusal
of treatment, knowledge of HIV status, clinical stage, and
depressive symptoms, male gender, and changes in health
s t a t u s( i m p r o v e m e n ta sw e l la sd e t e r i o r a t i o n )h a v ea l s o
been identiﬁed as important factors which aﬀect adher-
ence to HAART (highly active antiretroviral treatment) in
pediatric patients [22, 27–30, 32]. Denial and fear of HIV
status, misinformation, and misconceptions about HIV (for
instance beliefs that ART cures HIV [16]), low availability,
accessibility, and acceptance of therapy are some of the
obstacles among HIV-infected adolescents.
It is known that mothers tend to hide HIV infection
status from their children and disclosure is often delayed
until adolescence [33]. Reddi and colleagues show that
only 7.9% children had been made aware of their own
HIV infection status in their study in South Africa [34].
Disclosure of HIV infection status is a critical step and has
obvious implications for adherence. Starting the disclosure
process as early as 8-9 years of age and combining it with
speciﬁc support, as suggested (http://www.hivatis.org)m a y
result in increased adherence in children. There are similar
reports that indicate lack of disclosure as predictors of
poor adherence in adults [35]. Self-perceived family support
and/or the family’s and the household’s knowledge of the
patient’s HIV infection status are considered important
predictors of adherence [36].
1.3. Stigma- and Discrimination-Related Challenges. Stigma,
on top of the general knowledge of the population about
HIV/AIDS and ART treatment, is an important determinant
of adherence in the settings of sub-Saharan countries
according to studies conducted recently [17, 37–39].
Social or family stigmatization and fear of the conse-
quences of revealing HIV infection status to sexual partners
are closely related to poor adherence [40]. Family plays a
crucial role in any kind of treatment in children [41]o r
adults [42]. Major issues related to family or caregiver that
inﬂuence adherence include presence of anxiety; depression
[37, 43, 44]; active substance abuse [37]; the presence of HIV
infection in another family member; fear of disclosure of
HIV positivity to the family; family disruptions; belonging
to racial minorities or other vulnerable groups of the
population.
Familyandc ommunitymemberscanbothpla yapositiv e
andnegativerolesinARTtreatmentinitiationandadherence
[42, 45]. For instance, the stigma associated with HIV infec-
tion or AIDS may be more severe than that of other illnesses,
creating barriers to treatment initiation and support for
adherence that might otherwise be available [42, 46]. On
the positive side, family members and friends can play the
roleoftreatmentpartnersandprovidemuchneededsupport
[39, 42, 47].
Patients need to be encouraged by health care workers
to disclose their status. However, studies of interventions
to facilitate disclosure are lacking. Social institutions like
the church, nongovernmental organizations (NGOs), and
food aid services play a crucial role in issues ranging from
creating awareness about the illness, mobilizing support,
facilitating treatment, and promoting adherence [16, 42,
48]. For instance, in an evaluation program about the
impact of family nutritional support during the ﬁrst year
of antiretroviral treatment in the west Africa region, family
nutritional support for persons living with HIV initiating
antiretroviral treatment showed a positive impact after six
months [49].
1.4. Substance- Abuse-Related Challenges. Drug abuse and
alcohol consumption are factors that further threaten proper
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activealcoholuseandsubstanceabusemakesitmorediﬃcult
for patients to adhere to treatment [50–53]. For instance, in
Botswananearly40percentofthepatientssurveyedadmitted
missing a dose because of alcohol consumption [46]. Similar
studies also indicate that alcohol is highly related to reduced
adherence [54]. A systematic review in 2009 found that
HIV/AIDS patients that used alcohol are 50–60% more likely
to adhere less to their prescribed medications [55].
1.5.SocioeconomicChallenges. Thepatternsofinfectionhave
been shown to vary globally depending on the social and
economic conditions of the country aﬀected, with poverty
havingasigniﬁcantroleasasocialdeterminantofHIV/AIDS
and the spread of the virus as well as access and adherence to
ART treatment [42, 56].
Common reasons reported for missed doses include
ﬁnancial trouble [38, 57] that prevent caregivers of chil-
dren or adult patients from collecting medication on time
[42], distance barrier or lack of transportation facilities to
the ART clinic [37, 46], vomiting of medication without
redosing, incorrect dosing by a caregiver, missed clinic
appointments and pharmacy collections, confusion between
multiple caregivers, and self-discontinuation or refusal by
children [34, 58, 59]. Furthermore, patients’ beliefs that
medications need to be taken with food leads them to avoid
taking medications whenever food is unavailable, interfering
with adherence [42, 60]. Sometimes patients are forced
to choose between paying for transportation to the ART
facility and using the money for food [42, 57, 61]. Studies
in Uganda and Tanzania reported that transportation costs
are considered serious obstacles to taking ART [62, 63].
This has implications not only for day-to-day adherence
but also losses to follow up [64]. Determinants of ART
adherence for HIV-infected persons in sub-Saharan Africa
were examined with ethnographic research methods at HIV
treatment sites in Jos, Nigeria, Dar es Salaam, Tanzania,
and Mbarara, Uganda. The ﬁndings indicate that individuals
taking ART routinely overcome economic obstacles to ART
adherencethroughanumberofdeliberatestrategiesaimedat
prioritizing adherence: borrowing and “begging” transport
funds, making “impossible choices” to allocate resources in
favor of treatment, and “doing without” [65].
1.6. Medication-Related Challenges. Good adherence (i.e.,
more than 95%) was associated with beliefs regarding
the positive impact of the medications on participants’
quality of life. Characteristics of the commercially available
drug formulations such as taste, palatability, size of pills,
availability of liquid formulations, and adverse eﬀects (e.g.,
metabolic complications, lipodystrophy) can signiﬁcantly
aﬀectadherence.Furthermore,thecomplicatedregimen[66]
to be followed, such as the need for daily administration,
dietary restriction, drug interactions, frequency of dosing,
dosage, and therefore pill burden or amount of liquid, also
inﬂuence child’s adherence to therapy [26, 28, 31, 32, 56].
The above-mentioned medication-related factors are crucial
in determining children’s adherence to ART.
Chesney [27] reported that factors associated with
nonadherence included housing instability and length of
treatment with antiretroviral therapy. According to a report
by Van Dyke et al. [67], the main reasons mentioned
by patients for nonadherence were taste (16%) and child
refusal (16%) for ritonavir, and taste (9%) and interference
of medication schedule with lifestyle (10%) for nelﬁnavir
[67]. Side eﬀects are also usually associated with irregular
medication intake or stopping medication altogether.
1.7. Health-Care- and Systems-Related Challenges. Structural
factors not directly related to patient or medications can
also inﬂuence adherence. Some researchers have even con-
tended that these could be the most important barriers to
ART adherence in resource limited settings [5]. Limited
availability and accessibility of antiretroviral medications
and healthcare facilities for diagnosis and treatment of
HIV/AIDs, out-of-pocket payments, high cost of ART and
other health services, presence of healthcare providers expe-
rienced in ART provision, patient-nurse and other provider
relationships, health care providers’ beliefs, waiting time and
opening hours [16, 42, 59, 68–70], availability of counseling
services, and social, economic, or psychological support
for people living in both developing as well as developed
countries can inﬂuence adherence positively or negatively
[28]. Ensuring the privacy of ART clinics and waiting areas
need to be given special emphasis as authors of this paper
and others documented [16, 42]. For instance, Skovdal and
colleagues reported about patients who refused to leave
consultation rooms citing to nurses Mr. so and so is outside
[42].
Adherence support and clinic policies are also important
predictors of adherence [37]a sw e l la sl a c ko fa d h e r e n c e
monitoring mechanisms [10]. A recent study from South
Africa indicates that improving adherence is cost eﬀective
and helps to reduce health care costs especially those of
hospital care [71].
1.8. Interventions to Improve Adherence. Continuous mon-
itoring of both adherence and correlating it with clinical
outcomes will create an interactive feedback mechanism that
could lead to optimal clinical states and improved quality
of life for patients. There are needs for further research
and development in the area of ART adherence, adherence
support, and patient behavior.
Diagnosing and treating health problems such as depres-
sion, reducing substance abuse, improving patient and
provider relationship, counseling and enhancing family, and
community support mechanisms are shown to improve
adherence, as well as intervening on modiﬁable barriers to
adherence before starting ART [72, 73]. A meta-analysis by
Amico and colleagues indicated that adherence interventions
may be eﬃcacious when targeted at individuals who are
identiﬁed or anticipated to have poor adherence [74].
The few investigations of interventions indicate that
electronicreminders,pillorganizers,medication-eventmon-
itoring systems (MEMS) to record dosing behavior, use of
internet, educations services, use of phones [75], and so
forth can also enhance adherence. However, most of these
technologies have not had thorough scientiﬁc evaluation and
their eﬃcacy and cost eﬀectiveness may not be as high as4 AIDS Research and Treatment
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Figure 1: Identiﬁed factors for the challenges of adherence to ART.
expectations [5, 72, 76]. Cell phone message reminders and
web-based interventions require patient resources and liter-
acy which could create obstacles to their applicability in sub-
Saharan Africa. A recent systematic review published by the
Cochrane Database of Systematic Reviews reached similar
conclusions. It cited diverse methodological problems and
issues of study quality, among others as problems underlying
the scant evidence on adherence improvement interventions
and called for standardized and methodologically rigorous
trials of interventions to improve and measure adherence to
antiretroviral treatment [77].
2. Discussion
African HIV/AIDS patients have similar or higher adher-
ence levels compared to those of developed countries.
The challenges of adherence to ART identiﬁed include
factors related to patients and their families, socioeconomic
factors, medication, and healthcare systems as summarized
in Figure 1. This has implications for interventions to
improve ART adherence and therefore the program needs
to address these interrelated and multidimensional factors
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and retention requires an understanding of the multiple
barriers that patients face and developing interventions
that overcome these barriers. Long-term maintenance of
adherencerequirestheintegrationoftheseinterventionsinto
sustainable programs that ensure a reliable supply of drugs,
patient education, and ongoing support [80].
Low adherence to treatment has been associated with
higher hospitalization rates, productivity loss, disease pro-
gression, and death in both high-income and resource-
limited settings [35]. It is clear that adherence problems can
constitute a signiﬁcant barrier to ART programs in African
countries or elsewhere. Without regulated access to ART,
rapidemergenceofdrug-resistantviralstrainsandindividual
treatmentfailure is a potential threat and could curtail future
treatment options and leading to the transmission of drug
resistant strains of HIV [18]. We have identiﬁed that in order
to increase adherence to the appropriate level there needs
to be concerted eﬀorts to evaluate and conduct operational
research on ART service provision. These include use of new
monitoring mechanisms, infrastructure, staﬃng, training of
counselors, community support systems, and suitable drug
formulations [78]. But currently there are several research
gaps such as lack of capacity to survey the level of drug
resistance in sub-Saharan Africa and testing of new tools for
monitoring adherence.
This paper mainly focused on studies conducted on
African HIV/AIDS patients. As a result, the predictors of
ART adherence identiﬁed in the review may not necessarily
be applicable to countries outside the region. Furthermore,
currently there is no gold standard for measuring adherence.
Because of this, most of the studies included used the most
common forms of adherence assessment—patient recall and
pillcount—whichhaverecognizedbiases.Theseincludeover
reporting, recall, and social desirability bias [81–83]. We
measured inﬂuential factors for short-term to medium-term
adherence and that our conclusions on these factors may not
necessarily be extrapolated to losses to follow up or retention
to ART programs.
Health system barriers aﬀect adherence, especially a
regular and timely supply of medication to patients. An
unreliable supply of medications can severely reduce patient
adherence rates. In the majority of the sub-Sahara Africa
countries they are manifested by weak procurement and
supply management systems that lead to frequent shortages
of ART and other essential inputs. In a survey of 91 low- and
middle-income countries in 2008, 34% had experienced at
least one stock out of a required ART medication [4].
In the future, it is possible that the encouraging trend
of increased access to ART access may be further scaled
up if governments and donors continue their commitment
to the program. However, it is important that national
governments take an increasing role in the program in order
tomakeitsustainable.Theseincludechannelingoffundsand
policy commitments toward evaluation and improvement
of the program. These also call for scale up of eﬀorts to
prevent the virus. In addition, policy measures to improve
the socioeconomic status and empowerment of their citizens
in general are very important.
3. Conclusion andRecommendations
There is a relatively modest level of adherence to antiretro-
viral treatment among HIV/AIDS patients in sub-Saharan
Africa. However, it is challenged by a range of hierarchical
and intricately related factors and there is substantial room
for improvement of the ART programs in the region.
Vulnerable groups such as children and adolescents need
special attention by health workers and policy makers. There
is also a need for adherence indicators and interventions that
are applicable in the setting of developing countries.
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